HEPATOCELLULAR CARCINOMA

This study tests a high-precision radiation treatment called SBRT in 139 adults with liver cancer who are waiting for a liver transplant but cannot receive standard bridging treatments like radiofrequency ablation or chemoembolization. The goal is to see if SBRT can successfully …

This early-stage trial tests a new treatment for children and young adults with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The m…

This study tests a drug called cabozantinib in 20 adults whose liver cancer came back after a liver transplant. The goal is to see if the drug can control the cancer and slow its growth. Participants take the drug until it stops working or side effects become too severe.

This early-phase study tests a drug called tirapazamine, which becomes active in low-oxygen areas, combined with a procedure that blocks blood flow to liver tumors (embolization). The goal is to find the safest and most effective dose for people with liver cancer or liver-dominan…

This study tests an experimental pill called TTI-101 in people with advanced liver cancer that cannot be removed by surgery. The trial has two phases: first, finding the safest dose, then checking if the drug shrinks tumors when used alone or with standard immunotherapy drugs. Ab…

This study tests a two-step treatment for people with advanced liver cancer or stomach cancer that has spread to the liver. First, a drug called tirapazamine is injected directly into the liver's blood vessels to block and kill tumor cells. Then, patients receive nivolumab, an im…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with relapsed or hard-to-treat solid tumors. The goal is to find safe doses and see if the treatment shrinks tumors. The trial has two parts: fir…

This study tests whether a special nutrition drink (immunonutrition) taken before liver surgery can improve recovery in 100 adults with liver tumors. Participants are randomly assigned to receive the drink or standard care. The goal is to see if it reduces complications, shortens…

This study tests new immune-boosting drugs, alone or with other cancer treatments, in people with advanced liver or bile duct cancer. The goal is to see if these drugs can shrink tumors or slow the disease. About 294 adults whose cancer has spread or cannot be removed by surgery …

This study is testing whether combining two drugs, envafolimab and lenvatinib, can shrink tumors in people with advanced solid tumors (like lung, kidney, or liver cancer) who have run out of standard options. About 170 adults will receive the combination to find the best dose and…

This study tests a new drug, BAY 3547926, for people with advanced liver cancer that has a specific protein called GPC3. The drug delivers a small amount of radiation directly to cancer cells to kill them while sparing healthy tissue. About 148 participants will receive different…

This study tests a combination of drugs (cabozantinib, ipilimumab, nivolumab) and a procedure called TACE in people with liver cancer that cannot be removed by surgery or treated with a transplant. The goal is to see if this approach can stop the cancer from growing for at least …

This study tests an experimental drug called AZD9793 in people with advanced solid tumors, especially liver cancer, that have a specific marker called GPC3. The drug is designed to help the body's immune T cells find and attack cancer cells. The main goals are to check safety and…

This study is testing whether giving two drugs (sintilimab and bevacizumab) before surgery can help prevent liver cancer from coming back in people whose cancer has spread beyond the usual Milan criteria. About 37 adults with resectable liver cancer will receive the drug combinat…

This early-stage study tests a new drug called ZW251 in about 100 people with advanced liver, lung, or germ cell cancers that have not responded to other treatments. ZW251 is designed to deliver a cancer-killing agent directly to tumor cells that carry a specific marker (GPC3). T…

This study is for people with liver cancer who have had surgery to remove the tumor but are at high risk of the cancer returning. It tests whether adding a procedure called TACE (which delivers chemotherapy directly to the liver) after surgery can help keep the cancer away longer…

This study tests whether adding the drugs atezolizumab and bevacizumab before and after standard radiofrequency ablation can lower the chance of liver cancer returning. About 202 adults with small liver tumors (less than 3 cm) will be randomly assigned to ablation alone or ablati…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests whether giving focused radiation before surgery for a single liver cancer nodule is safe and does not delay or cancel the planned operation. About 30 participants will receive radiation followed by surgery. The goal is to see if this approach can reduce the risk …

This early-phase study tests a new drug called JMT106 in about 200 adults with advanced solid tumors (including lung and liver cancer) who have run out of standard options. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants…

This study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…

This study tests a new way to treat advanced liver cancer by using artificial intelligence to find the best dose of three drugs for each patient. The goal is to make treatment more effective while reducing side effects. About 12 adults with advanced liver cancer who cannot have s…

This study tests whether giving chemotherapy directly into the liver plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from coming back in high-risk patients. About 39 adults with liver cancer that is …

This early-phase study tests whether combining targeted radiation beads (SIRT) with two immunotherapy drugs (tremelimumab and durvalumab) is safe and effective before liver cancer surgery. About 20 adults with resectable liver cancer will receive the treatment and then undergo su…

This study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that still has active tumors after a prior treatment called TARE. The goal is to see if this approach can safely shrink or control those remaining tumors. About 48 adults with…

This study looks at whether giving the immunotherapy drug tislelizumab at different infusion times after surgery can help prevent liver cancer from coming back in high-risk patients. About 33 adults aged 18-75 with early-stage liver cancer who had curative surgery and are at high…

This study tests a new treatment plan for people with advanced liver cancer that has spread to the main blood vessel or to a few other spots in the body. The treatment combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiatio…

This study tests whether a new drug called rilvegostomig, given with bevacizumab (with or without another drug, tremelimumab), helps people with advanced liver cancer live longer. About 1220 adults whose cancer cannot be removed or treated with local therapies will take part. The…

This study tests whether a newer, ultrasound-guided endoscopic procedure can better prevent dangerous rebleeding from enlarged veins in the stomach or esophagus compared to standard endoscopic treatments. The trial enrolls 84 liver cancer patients who have already had a bleeding …

This study tests a combination of two types of drugs (anti-PD-1/PD-L1 and anti-VEGF) in 50 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and helps shrink tumors or slow their growth. Participants will receive the …

This study tests a treatment for advanced liver cancer that delivers chemotherapy directly to the liver through a thin tube, combined with a gentle embolization agent (lipiodol) to block tumor blood supply temporarily. The goal is to shrink tumors while keeping the liver working …

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This early-phase study tests a new treatment that takes a person's own immune cells, modifies them in a lab to better recognize and attack cancer cells, and then returns them to the patient. It is for adults with advanced solid tumors that express a protein called GPC3, such as l…

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has not responded to other treatments. The goal is to see if the drug can shrink tumors. About 40 adults will take part, and they will receive the drug through an IV.

This study tests a combination of two or three drugs (cabozantinib, durvalumab, and possibly tremelimumab) in people with advanced stomach, esophageal, liver, or colorectal cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the treatment can …

This study tests whether taking prednisone, a steroid, before and during radiation therapy can protect the liver in people with liver cancer. About 20 participants will take prednisone for a few days around their radiation sessions. The goal is to see if it reduces liver inflamma…

This study tests whether adding a cancer vaccine (UCPVax) to standard treatment (atezolizumab plus bevacizumab) can shrink tumors better than standard treatment alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior s…

This study tests a new treatment called RP2, a virus that attacks cancer cells, combined with other drugs for people with advanced liver or bile duct cancer that has not responded to first treatment. About 60 adults will take part. The goal is to see if the combination shrinks tu…

This study is for people with advanced liver cancer (BCLC stage C) that has spread to blood vessels or other organs. It compares standard drug therapy alone versus drug therapy plus a precise type of radiation called SBRT. The goal is to see if adding radiation helps people live …

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This study tests whether combining three drugs—atezolizumab, bevacizumab, and memantine—can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. About 19 adults with newly diagnosed, untreated hepatocellular carcinoma will receive the triple thera…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors more effectively in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and …

This study tests a new drug called SIM0610 in adults with advanced solid tumors (cancers that have spread). The main goals are to check safety and find the right dose. About 260 people with certain cancers like lung, colon, head and neck, or liver cancer can join. The study has t…

This study tests a new three-drug combination for people with advanced liver cancer that cannot be removed by surgery. The drugs work together to boost the immune system and block cancer growth. About 40 participants who have not had prior systemic therapy will receive the treatm…

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that has not responded to standard therapy. The first part checks safety and the best dose, while the second part compares the drug's effectiveness against another appr…

This study tests whether adding a liver-directed chemotherapy (GEMOX) to a standard immunotherapy combination (durvalumab + tremelimumab) works better than immunotherapy alone for people with advanced liver cancer that has a high tumor burden. About 196 adults with liver cancer t…

This early-phase study tests a new drug, QXL138AM, for safety and tolerability in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. Participants must have tried standard treatments without success. The study will also look…

This study tests whether combining Y90 radiation therapy with two drugs (atezolizumab and bevacizumab) can shrink liver tumors enough for patients to qualify for a liver transplant. About 40 adults with liver cancer will receive this treatment. The goal is to see if the tumors sh…

This study tests a single injection of IP-001 given right after liver cancer treatment (surgery or heat ablation) to see if it can keep the cancer from returning. It involves 126 adults with hepatocellular carcinoma at high risk of recurrence. Participants are followed with regul…

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This study compares a three-drug combination (durvalumab, tremelimumab, and lenvatinib) against a two-drug combination (durvalumab and tremelimumab) in 140 adults with advanced liver cancer that cannot be removed by surgery. Participants must not have had prior systemic treatment…

This study is for people with advanced liver cancer that cannot be removed by surgery. It combines a precise type of radiation (carbon ion radiotherapy) with two standard drugs (atezolizumab and bevacizumab) to see if the radiation helps control the tumor better. About 52 adults …

This study tests a new treatment approach for people with liver cancer that has spread into the portal vein (a major blood vessel). The treatment combines radiation therapy before surgery with an immunotherapy drug (camrelizumab) and a targeted therapy pill (apatinib) given befor…

This study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is t…

This early-stage trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. The treatment combines freezing the tumor (cryoablation) with a targeted drug infusion into the liver, followed by two immunotherapy drugs. The main goal is to che…

This study tests a new experimental drug called CVM-1118 combined with the immunotherapy nivolumab in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will receive the combination to see if it shrinks tumors and how long any benefit lasts. The …

This early-phase study tests a new drug called MT-303 in about 70 adults with advanced liver cancer that has spread or cannot be removed. The drug targets a protein (GPC3) found on these cancer cells. The main goals are to check safety, find the best dose, and see if it works whe…

This study tests whether adding a PD-1 inhibitor (a type of immunotherapy) after standard microwave ablation can help prevent early-stage liver cancer from returning. About 200 adults with early liver cancer who have no signs of remaining tumor after ablation will receive the dru…

This study tests a personalized vaccine made from a patient's own immune cells, combined with an immunotherapy drug (nivolumab), after surgery to remove liver cancer or colorectal cancer that spread to the liver. The goal is to see if this treatment can prevent the cancer from re…

This study tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, in 32 people with advanced liver cancer who also have moderate liver cirrhosis (Child-Pugh-B). The main goal is to see if this treatment is safe and tolerable. The study focuses on patients of…

This study tests a drug called 177Lu-PSMA-617 in people with liver cancer that has spread and shows a specific marker (PSMA) on scans. The drug delivers radiation directly to cancer cells. The trial aims to see if this approach is safe and can help control the disease. About 10 a…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to at least two prior therapies. The treatment uses specially engineered immune cells to attack cancer cells. The goal is to check safety and find the best dose, with early…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This early-phase study tests whether adding focused radiation (SBRT) to a standard immunotherapy combination (atezolizumab and bevacizumab) is safe and tolerable for people with advanced liver cancer that cannot be removed by surgery. About 18 participants will receive repeated d…

This study tests if memantine, a drug used for Alzheimer's, can help control advanced liver cancer in people with severe cirrhosis. About 12 adults with liver cancer that cannot be surgically removed will take memantine alone. Researchers will track how long the cancer stays stab…

This study tests whether combining the drug regorafenib with a type of internal radiation (Y-90) can control advanced liver cancer that cannot be removed by surgery. About 30 adults with unresectable hepatocellular carcinoma will receive the combination. The goal is to see how ma…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding a drug that blocks a cancer cell survival process (autophagy) can make standard TACE therapy work better for liver cancer. TACE cuts off blood supply to the tumor, but cancer cells often survive by eating themselves. The new approach aims to kill m…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, in 246 liver cancer patients in Korea. It observes patients already receiving these drugs as part of their normal care, without adding new treatments. The goal is to see how well the drugs work and…

This early-stage study tests a new treatment called C-CAR031 for people with advanced liver cancer that cannot be removed by surgery. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The main goals are to see if it is safe and whether it ca…

This study tests a new ultrasound method to find liver cancer earlier and more accurately. About 328 adults at risk for liver cancer will get both standard and new ultrasound scans. The goal is to see if the new method can spot tumors that standard ultrasound might miss, helping …

This study compares two ways to screen for liver cancer in people with cirrhosis who are at high risk. About 944 participants will either get a standard ultrasound every six months or an ultrasound plus a quick MRI (Fast-MRI). The goal is to see if adding Fast-MRI finds more earl…

This study tests whether a quick, dye-free MRI scan can find liver cancer earlier than the standard ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both an ultrasound and a short MRI every 6 months for 2.5 years. The goal is to see if the MRI c…

This study aims to develop a blood test that can accurately distinguish between two common types of liver cancer—hepatocellular carcinoma and cholangiocarcinoma—before surgery. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal i…

This study tests whether a special imaging scan called PYLARIFY PET-CT can accurately detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan to see if it matches standard methods. The goal is to improv…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study tests whether a shorter, safer MRI scan can find returning liver cancer as well as the usual CT scan. It involves 455 adults who have been cancer-free for at least two years after treatment. The goal is to reduce radiation and contrast dye risks while still catching ca…

This study tests whether a dietary supplement called β-alanine can reduce fatigue in people with advanced liver cancer who are receiving standard immunotherapy. About 158 participants will take either the supplement or a placebo alongside their regular treatment. The main goal is…

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…

This study tests whether a mushroom extract called Antrodia cinnamomea can help liver cancer patients recover liver function and feel better after a procedure called TACE (chemoembolization). About 60 adults with liver cancer will take the extract or a placebo for 28 days after T…

This study aims to find biological markers that can predict how well liver cancer patients respond to a combination of two immunotherapy drugs (tremelimumab and durvalumab). Researchers will follow 120 adults with advanced liver cancer who have not had prior systemic treatment. T…

This study is testing a new blood test called Elecsys® GAAD to see if it can find liver cancer earlier in people with liver cirrhosis. Current methods often catch the cancer too late, leaving few treatment options. Researchers will compare the new test with standard tests in 600 …

This study is testing whether a protein called Glypican-3 (GPC-3) in the blood can help predict how well patients with advanced liver cancer respond to a common immunotherapy combination (Atezolizumab plus Bevacizumab). Researchers will measure GPC-3 levels before treatment, at 3…

This study is for people with advanced liver or colorectal cancer that has stopped responding to standard treatments. Researchers will take a small sample of the tumor, grow it in the lab as a 3D 'organoid,' and test different drugs on it to find which one works best. The goal is…

This study creates miniature, 3D copies of liver tumors from 150 patients to test how well different treatments work. Researchers will also study the tumor's environment and the connection between the gut and liver. The goal is to better understand why some patients respond to th…

This study looks at how often a specific gene change (BAP1 mutation) occurs in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. The…

This observational study is exploring whether levels of a protein called Galectin-3 in the blood are linked to how well patients with kidney, lung, bladder, or liver cancer respond to immunotherapy drugs (PD-1/PDL-1 inhibitors). Researchers will measure Galectin-3 before each tre…

This study looks at 300 liver cancer patients who cannot have surgery and are receiving a treatment called TACE. Researchers will use artificial intelligence to analyze routine CT scans taken before treatment, measuring body composition like organ size and tissue health. The goal…

This study looks at whether taking a blood sample from the vein that drains directly from a liver or pancreas tumor gives more useful genetic information than a standard arm vein sample. About 15 adults scheduled for a biopsy will provide both samples, and researchers will compar…

This study is testing whether a simple blood test that looks for tiny bits of tumor DNA (ctDNA) can predict if liver cancer will come back after surgery. Researchers will take blood samples before and after surgery, and at 3 and 6 months, from 150 adults with liver cancer. The go…

This study is testing two scoring systems (PLEASE and M10S20) to see if they can predict serious liver problems, including liver cancer, in 600 people with advanced chronic liver disease. Participants are split into two groups: one gets standard check-ups every six months, while …

This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China, who received treatments like chemotherapy, targeted therapy, or immunotherapy before surgery. The goal is to figure out which treatments work best and which patients benefit the most.…

This study looks at whether a special ultrasound (contrast-enhanced ultrasound) can better show if liver cancer treatment (radioembolization) killed the tumor, compared to standard CT or MRI scans. About 30 adults with liver cancer will get an ultrasound within two weeks of their…

This study looks at the medical records of 15,000 people to understand how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are connected to other health problems. Researchers will track who develops liver cancer or serious liver complications over time. The go…

This study is collecting data from 1500 people with liver tumors who are getting a treatment called thermal ablation, which uses heat to destroy cancer. The goal is to use artificial intelligence to better predict who will benefit most and how to plan the treatment. This research…

This study aims to find out why some people with fatty liver disease or alcohol-related liver disease develop liver cancer. Researchers will look at genetic markers, immune system factors, and medical images from 710 adults with and without cirrhosis. The goal is to catch early s…

This study aims to understand how the immune system and genes change in people with advanced liver cancer during immunotherapy. Researchers will collect blood and tumor samples from 50 participants before and during treatment. The goal is to find biomarkers that predict how well …

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.

This early-phase study tests whether a special PET scan (18F-FSPG) can help guide treatment for liver cancer (hepatocellular carcinoma). About 60 participants will receive standard Y90 radioembolization therapy, and researchers will compare scan results with blood markers (ctDNA)…

This study aims to uncover the genetic and molecular causes of liver cancer in children. Researchers will analyze DNA, gene activity, and other markers from up to 1,600 participants, including children with liver tumors and their biological relatives. The goal is to better classi…

This study looks at a method called 'Teaching the Teachers' to see if it helps spread guidelines for diagnosing liver cancer. Researchers will train expert radiologists, who then teach other doctors. The goal is to see if this approach increases how often the guidelines are used …

This study tracks 20 adults with chronic hepatitis delta (a serious liver infection) who are starting a new drug called bulevirtide. Researchers want to see how the drug changes the gut's bacteria and bile acids over 48 weeks, and how those changes relate to inflammation and live…

This study looks at why some people with liver cancer are diagnosed late. Researchers will survey 730 patients about things like transportation, food, and housing that may make it hard to get early cancer care. They will also interview doctors and community leaders to understand …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…